(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate

We are (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate CAS:376608-71-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate
CAS.NO:376608-71-8
Synonyms:(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate
(1R,2R)-2-(3,4-Difluorophenyl)cyclopropanaminium hydroxy(phenyl)acetate
trans-(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-2-hydroxy-2-phenylethanoate
(1R,2R)-2-(3,4-difluorophenyl) cyclopropanamine(S)-(carboxylato(phenyl) methyl)holmium
(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine,(2R)-2-hydroxy-2-phenylacetic acid
 
Physical and Chemical Properties:
Molecular Formula C17H17F2NO3
Molecular Weight 321.319
 
Specification:
Appearance:White or off-white powder
Assay(HPLC):≥95.0%
Total impurities:≤5.0%
Enantionmer:≤2.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ticagrelor(CAS:274693-27-5).

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate


Related News: Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Cyclotrisiloxane, 2,4,6-triethenyl-2,4,6-trimethyl- CAS:3901-77-7 After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.2,4,5,6-Tetraaminopyrimidine sulfato CAS:5392-28-9 After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.2-isopropilfenol CAS:88-69-7 After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.After nearly ten years of growth, China’s fine chemical industry has made considerable progress. At present, China’s overall refinement rate (that is, the output value rate of fine chemicals = total value of fine chemical products / total value of chemical products * 100%) has reached about 40%. Some fine chemical products have certain international competitiveness and become important processing and exporting places of fine chemical raw materials and intermediates in the world.

Related Products
Product Name
2-Cyano-3,5-difluoropyridine View Details
2-PHENYLBUTYRONITRILE View Details
4-Methyl-5-vinylthiazole View Details
Hexamethylcyclotrisiloxane manufacturer Fmoc-D-2-Nal-OH manufacturer Methyl 2-methoxy-5-sulfamoylbenzoate manufacturer N-(4-bromophenyl)-N-biphenylylamine manufacturer potassium hydroxide manufacturer